
US Patent No: 6,749,868
Number of patents in Portfolio can not be more than 2000
Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
Stats
-
Jun 15, 2004
Issued date -
May 21, 1999
filing date -
09/316,642
serial no -
In Force
status
Importance
Abstract
In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful election of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein.
First Claim
Related Publications
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art
| Patent Info | (Count) | # Cites | Year |
|---|---|---|---|
|
|
|||
| 5,439,686 Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor | 152 | 1993 | |
| 5,498,421 Composition useful for in vivo delivery of biologics and methods employing same | 209 | 1994 | |
| 5,916,596 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof | 110 | 1996 | |
| 6,096,331 Methods and compositions useful for administration of chemotherapeutic agents | 69 | 1997 | |
| 6,537,579 Compositions and methods for administration of pharmacologically active compounds | 49 | 2000 | |
|
|
|||
| 5,714,520 Propofol compostion containing edetate | 37 | 1995 | |
| 5,731,355 Pharmaceutical compositions of propofol and edetate | 39 | 1997 | |
| 5,731,356 Pharmaceutical compositions of propofol and edetate | 21 | 1997 | |
| 5,908,869 Propofol compositions containing edetate | 21 | 1998 | |
|
|
|||
| 6,028,108 Propofol composition comprising pentetate | 16 | 1998 | |
| 6,177,477 Propofol formulation containing TRIS | 15 | 1999 | |
|
|
|||
| 4,344,934 Therapeutic compositions with enhanced bioavailability | 36 | 1980 | |
|
|
|||
| 6,399,087 Propofol formulation with enhanced microbial inhibition | 12 | 2000 | |
|
|
|||
| 6,100,302 Propofol formulation with enhanced microbial characteristics | 16 | 1999 | |
|
|
|||
| 5,504,102 Stabilized pharmaceutical composition and stabilizing solvent | 53 | 1995 | |
|
|
|||
| 5,683,715 Taxane-containing phosphatidylcholine liposomes | 27 | 1995 | |
|
|
|||
| 5,399,363 Surface modified anticancer nanoparticles | 176 | 1992 | |
|
|
|||
| 6,147,122 Propofol composition containing sulfite | 16 | 1999 | |
|
|
|||
| 6,469,069 Propofol composition containing sulfite | 14 | 2000 | |
|
|
|||
| 5,648,090 Liposome encapsulated toxol and a method of using the same | 21 | 1995 | |
|
|
|||
| 6,140,373 Propofol composition | 15 | 1998 | |
|
|
|||
| 6,150,423 Propofol-based anesthetic and method of making same | 15 | 1998 | |
|
|
|||
| 5,626,862 Controlled local delivery of chemotherapeutic agents for treating solid tumors | 134 | 1994 | |
|
|
|||
| 5,565,478 Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs | 40 | 1994 | |
|
|
|||
| 5,744,460 Combination for treatment of proliferative diseases | 26 | 1996 | |
|
|
|||
| 5,977,163 Water soluble paclitaxel prodrugs | 156 | 1997 | |
|
|
|||
| 5,637,625 Propofol microdroplet formulations | 39 | 1996 | |
|
|
|||
| 5,543,152 Sphingosomes for enhanced drug delivery | 69 | 1994 | |
|
|
|||
| 5,731,334 Method for treating cancer using taxoid onium salt prodrugs | 6 | 1995 | |
|
|
|||
| 5,962,536 Injectable propofol formulations | 13 | 1998 | |
|
|
|||
| 6,362,234 Water-soluble prodrugs of propofol for treatment of migrane | 18 | 2000 | |
|
|
|||
| 6,326,406 Clear, injectable formulation of an anesthetic compound | 13 | 2000 | |
Patent Citation Ranking
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Dec 15, 2015 |
| Fee | Large entity fee | small entity fee | micro entity fee |
|---|---|---|---|
| Surcharge - 11.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
| Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |